GSK’s Bold Move to Accelerate Drug Innovation | UK News

GSK is betting big on the UK’s scientific future, slashing nearly $2 billion in costs while pouring $400 million into life sciences over three years—centered on a brand-new Cambridge R&D hub for cancer, respiratory, and vaccine research. The move includes relocating 1,000 scientists and shuttering its Stevenage site by 2029, with staff and work shifting to Ware. This bold pivot, led by the new CEO, aims to turbocharge drug development, launch twice as many phase three trials, and position GSK squarely in the UK’s “golden triangle” alongside Oxford and London. It’s a major endorsement of British innovation—and a strategic counter to rivals who recently reversed course on UK investments. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/5bd26e7b35fd6b89